Mechanistic and inhibition studies on isocitrate dehydrogenase 1
<p>Genes encoding for IDH1 and IDH2 are frequently mutated in multiple cancer types including gliomas and AML. IDH variants, notably R132H IDH1, result in a gain-offunction leading to substantially enhanced production of the ‘oncometabolite’, 2- hydroxyglutarate. Drug development by pharmaceut...
Hlavní autor: | Liu, S |
---|---|
Další autoři: | Schofield, C |
Médium: | Diplomová práce |
Jazyk: | English |
Vydáno: |
2019
|
Podobné jednotky
-
The studies on the mechanism and inhibition of Isocitrate Dehydrogenases
Autor: Liu, X
Vydáno: (2022) -
Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
Autor: Li Su, a další
Vydáno: (2020-04-01) -
How robust are the data in vorasidenib for isocitrate dehydrogenase-1 or isocitrate dehydrogenase-2 mutant low-grade glioma?
Autor: Eric T Wong
Vydáno: (2023-01-01) -
Highlighting the mechanistic role of Olutasidenib (FT-2102) in the selective inhibition of mutated isocitrate dehydrogenase 1 (mIDH1) in cancer therapy
Autor: Elliasu Y. Salifu, a další
Vydáno: (2022-01-01) -
Differentiating inhibition selectivity and binding affinity of isocitrate dehydrogenase 1 variant inhibitors
Autor: Liu, S, a další
Vydáno: (2023)